Last week, Sarah Cannon, our global cancer institute, and HCA Midwest Health, Kansas City’s largest healthcare network, announced that they expanded their cancer collaboration through clinical research. By joining a global research network, HCA Midwest Health is now offering greater access to clinical trials for those facing cancer in the Kansas City region.

“Clinical trials are an integral part of advancing the standard of cancer care, as today’s trials are tomorrow’s cutting-edge treatments,” said Dr. Howard A. “Skip” Burris, III, president of clinical operations and chief medical officer at Sarah Cannon. “By expanding our collaboration, we can provide patients in Kansas City access to the latest therapies with the comfort of their physicians, family and friends close to home.”

Patients can access clinical trials throughout the entire HCA Midwest Health system. The initial strategic research sites where Sarah Cannon clinical trials will be conducted in the coming weeks include HCA-affiliate Menorah Medical Center and Research Medical Center. Additional sites are planned to launch in the near future.

Since 2014, HCA Midwest Health and Sarah Cannon have worked together to advance cancer services in Kansas City. Sarah Cannon Research Institute at HCA Midwest Health will be supported and complemented by the system’s seven hospitals, Belton Regional Medical Center, Centerpoint Medical Center, Lafayette Regional Health Center, Lee’s Summit Medical Center, Menorah Medical Center, Overland Park Regional Medical Center and Research Medical Center as well as numerous cancer care outreach sites located in communities throughout the region.

Learn more on the HCA Midwest Health Clinical Research Program here.